Drugs / CssBA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03404674 | Jan 2018 → Mar 2019 | diarrheal disease | PATH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06692907 | Mar 2025 → Apr 2026 | escherichia coli infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CssBA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06692907 ↗ |
| Modality | Vaccine | “prototype Coli surface antigen 6 (CS6) subunit vaccine (CssBA)” NCT03404674 ↗ |
| Route | Intramuscular | “given by intramuscular (IM) injection” NCT03404674 ↗ |